Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00575744 · ClinicalTrials.gov registry record · Phase 2
Sentinel Lymph Node Biopsy Using Peritumoral Injection With Blue Dye Confirmation
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 699
- Enrollment target
NCT00575744 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 699 participants.
The verdict
NCT00575744, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 699 participants
- Enrollment target
Study Summary
We continue to collect information in support of the hypothesis that the histology of the first draining lymph node (sentinel node) accurately predicts the histology of the rest of the axillary lymph nodes.
Interventions
- PROCEDURE Sentinel Node Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 699 participants |
| Start Date | 1998-12 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00575744
The ClinicalTrials.gov registry entry for NCT00575744 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 699 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sentinel Node Biopsy is the first listed.
NCT00575744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00575744 about?
NCT00575744 is a clinical study titled "Sentinel Lymph Node Biopsy Using Peritumoral Injection With Blue Dye Confirmation". We continue to collect information in support of the hypothesis that the histology of the first draining lymph node (sentinel node) accurately predicts the histology of the rest of the axillary lymph nodes.
What is the current status of trial NCT00575744?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 699 participants. The study started on 1998-12. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00575744?
The interventions under investigation include: Sentinel Node Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT00575744?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.